press release

January 14, 2022

– Company to Host Conference Call January 21st at 8:30 am ET to Discuss Results – CAMBRIDGE, Mass. (BUSINESS WIRE) Jan. 14, 2022 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 18 month results from the HELIOS A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the ...

press release

January 4, 2022

– Consistent Scientific Leadership Focused on Sustainable Innovation – CAMBRIDGE, Mass. (BUSINESS WIRE) Jan. 4, 2022 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President. Dr. Vaishnaw joined Alnylam in 2006 as Vice President, Clinical Research with roles of increasing responsibility, ultimately serving as President of Research and ...

press release

November 19, 2021

− Introduces New Near Term Opportunity for Vutrisiran in Stargardt Disease, Expected to Enter Phase 3 Development in Late 2022 – – Adds New Preclinical Cardiovascular Disease Programs, GEMINI CVR and “Gene X,” with Highly Transformative Potential – – Highlights Strong Progress in Extrahepatic Delivery of RNAi Therapeutics, Including Delivery in Muscle, Heart, and Adipose Tissue, and New CNS and Ocular ...

capella

November 19, 2021

On November 19, 2021, we hosted a virtual R&D Day event showcasing Alnylam's late stage clinical efforts, next wave programs, and platform advances. The event included presentations from Alnylam senior leaders as well as guest speakers. To view the webcast, click here. To view the R&D Day presentation, click here. Speakers Alnylam Management: John Maraganore, Ph.D. Chief Executive Officer ...

press release

November 13, 2021

– Single Doses of Investigational Zilebesiran Resulted in Sustained Serum Angiotensinogen and Blood Pressure Reductions Through Six Months, Supporting Quarterly and Potentially Biannual Dosing – – Blood Pressure Response to Low Salt Intake under the Peak Pharmacodynamic Effect of Zilebesiran was Consistent with Augmented Pharmacology, with No Hypotensive Adverse Events Reported – – Coadministration with Irbesartan Resulted in Additional Blood Pressure ...

press release

November 12, 2021

CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 12, 2021 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on November 19, 2021. The event will include presentations from Alnylam senior leaders as well as guest speakers. The virtual event ...

webcast

November 11, 2021

press release

November 8, 2021

– KARDIA 2 will Evaluate Efficacy and Safety of Zilebesiran when Used in Combination with Conventional Antihypertensive Medications – CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 8, 2021 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA 2, a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN AGT), ...

Web Page

November 1, 2021

Our Science SCIENTIFIC ADVISORY BOARD Our Scientific Advisory Board The scientific advisors and founders of Alnylam are among the world’s leaders in RNAi research as well as broad aspects of medical research. Learn more about the accomplishments of each of our highly regarded scientists by selecting a name below.Our Science SCIENTIFIC ADVISORY BOARD Our Scientific Advisory Board The scientific advisors and ...

Web Page

November 1, 2021

Our Science OUR SCIENCE Pioneering RNA interference (RNAi) Therapeutics RNAi therapeutics are an innovative new class of gene silencing medicines based on RNA interference (RNAi)—a breakthrough discovery in understanding how genes are regulated naturally within cells. The significance of the discovery of RNAi was recognized with the 2006 Nobel Prize in Medicine or Physiology. Since our founding in 2002, Alnylam has ...